NYSE:DPLO - Diplomat Pharmacy Stock Price, News & Analysis

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) released its quarterly earnings results on Friday, August, 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.01. The company earned $1.29 billion during the quarter, compared to the consensus estimate of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. Diplomat Pharmacy's quarterly revenue was down 9.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.05) earnings per share. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy issued an update on its FY19 earnings guidance on Friday, August, 9th. The company provided earnings per share (EPS) guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.

14 Wall Street analysts have issued 1-year target prices for Diplomat Pharmacy's stock. Their forecasts range from $4.00 to $30.00. On average, they expect Diplomat Pharmacy's share price to reach $9.6538 in the next twelve months. This suggests a possible upside of 70.9% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 3 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

News coverage about DPLO stock has trended somewhat positive this week, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Diplomat Pharmacy.

Some companies that are related to Diplomat Pharmacy include Covetrus (CVET), 111 (YI), Rite Aid (RAD), Petmed Express (PETS), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Activision Blizzard (ATVI), CVS Health (CVS), Cannabis Sativa (CBDS), Horizon Therapeutics (HZNP), Servicesource International (SREV), Ford Motor (F) and Cara Therapeutics (CARA).

Diplomat Pharmacy's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.07%), Stephens Inc. AR (8.83%), Vanguard Group Inc. (7.64%), JPMorgan Chase & Co. (1.94%), Northern Trust Corp (1.72%) and Invesco Ltd. (1.63%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Kenneth O Klepper, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Trexquant Investment LP, Wells Fargo & Company MN, Cubist Systematic Strategies LLC, Voloridge Investment Management LLC, Morgan Stanley, Kings Point Capital Management and Comerica Bank. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar and Kenneth O Klepper. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was purchased by a variety of institutional investors in the last quarter, including Stephens Inc. AR, JPMorgan Chase & Co., BlackRock Inc., Invesco Ltd., D. E. Shaw & Co. Inc., Charles Schwab Investment Management Inc., Vanguard Group Inc. and Renaissance Technologies LLC. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $5.65.

Diplomat Pharmacy has a market capitalization of $428.44 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]